BioCentury | Jun 8, 2015
Clinical News

Remitch nalfurafine regulatory update

...Ministry of Health, Labor and Welfare (MHLW) approved an expanded label for Remitch nalfurafine from Toray...
...will promote Remitch at medical institutions, and Torii will be responsible for distributing the drug. Toray...
...supply Remitch to Torii, which already markets the compound in Japan (see BioCentury, March 30). Toray Industries Inc....
BioCentury | Mar 30, 2015
Clinical News

Remitch nalfurafine regulatory update

...will promote Remitch at medical institutions and Torii will be responsible for distributing the drug. Toray...
...rights to the product in North America. Mitsubishi Tanabe Pharma Corp . (Tokyo:4508), Osaka, Japan Toray Industries Inc....
BioCentury | Mar 23, 2015
Financial News

Spectral Medical completes private placement

...C$5 million ($3.9 million) Shares: 9 million Price: C$0.55 Shares after offering: 188.8 million Investor: Toray...
BioCentury | Jun 16, 2014
Financial News

Spectral Diagnostics proposes private placement

...C$18.2 million ($16.7 million) Shares: 45.1 million Price: C$0.29 Shares outstanding prior: 134.5 million Investors: Toray...
...of C$13.2 million ($12.1 million) through the sale of 45.1 million shares at $0.29 to Toray...
...other existing investors and a second tranche of up to C$5 million ($4.6 million) to Toray...
BioCentury | Jan 27, 2014
Clinical News

Winfuran nalfurafine regulatory update

...EMA said Toray withdrew an MAA for Winfuran nalfurafine to treat severe uremic pruritus in patients...
...opioid receptor agonist has Orphan Drug designation in the EU to treat hemodialysis-related uremic pruritus. Toray...
...rights in Europe (see BioCentury, Oct. 31, 2011). Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Toray Industries Inc....
BioCentury | Jan 6, 2014
Clinical News

Winfuran nalfurafine regulatory update

...On Dec. 19, 2013, EMA's CHMP recommended against approval of an MAA from Toray for Winfuran...
...opioid receptor agonist has Orphan Drug designation in the EU to treat hemodialysis-related uremic pruritus. Toray...
...an oral formulation of the product in Japan as Remitch for the indication. In 2011, Toray...
BioCentury | Apr 8, 2013
Financial News

Spectral Diagnostics completes private placement

...C$5.6 million ($5.5 million) Shares: 18.7 million Price: C$0.30 Shares after offering: 119.9 million Investor: Toray...
BioCentury | Mar 25, 2013
Financial News

Spectral Diagnostics amends private placement

...C$5.6 million ($5.5 million) Shares: 18.7 million Price: C$0.30 Shares outstanding prior: 101.3 million Investor: Toray...
BioCentury | Mar 18, 2013
Financial News

Spectral Diagnostics proposes private placement

...C$5 million ($4.9 million) Shares: 16.7 million Price: C$0.30 Shares outstanding prior: 101.3 million Investor: Toray...
BioCentury | Jan 14, 2013
Emerging Company Profile

Trevi: Pain to itch

...according to Good. Toray Industries Inc. markets nalfurafine as Remitch in Japan to treat hemodialysis-related uremic pruritus. Toray...
...& Co. KGaA (Xetra:FRE), Bad Homburg, Germany Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Toray Industries Inc....
Items per page:
1 - 10 of 43
BioCentury | Jun 8, 2015
Clinical News

Remitch nalfurafine regulatory update

...Ministry of Health, Labor and Welfare (MHLW) approved an expanded label for Remitch nalfurafine from Toray...
...will promote Remitch at medical institutions, and Torii will be responsible for distributing the drug. Toray...
...supply Remitch to Torii, which already markets the compound in Japan (see BioCentury, March 30). Toray Industries Inc....
BioCentury | Mar 30, 2015
Clinical News

Remitch nalfurafine regulatory update

...will promote Remitch at medical institutions and Torii will be responsible for distributing the drug. Toray...
...rights to the product in North America. Mitsubishi Tanabe Pharma Corp . (Tokyo:4508), Osaka, Japan Toray Industries Inc....
BioCentury | Mar 23, 2015
Financial News

Spectral Medical completes private placement

...C$5 million ($3.9 million) Shares: 9 million Price: C$0.55 Shares after offering: 188.8 million Investor: Toray...
BioCentury | Jun 16, 2014
Financial News

Spectral Diagnostics proposes private placement

...C$18.2 million ($16.7 million) Shares: 45.1 million Price: C$0.29 Shares outstanding prior: 134.5 million Investors: Toray...
...of C$13.2 million ($12.1 million) through the sale of 45.1 million shares at $0.29 to Toray...
...other existing investors and a second tranche of up to C$5 million ($4.6 million) to Toray...
BioCentury | Jan 27, 2014
Clinical News

Winfuran nalfurafine regulatory update

...EMA said Toray withdrew an MAA for Winfuran nalfurafine to treat severe uremic pruritus in patients...
...opioid receptor agonist has Orphan Drug designation in the EU to treat hemodialysis-related uremic pruritus. Toray...
...rights in Europe (see BioCentury, Oct. 31, 2011). Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Toray Industries Inc....
BioCentury | Jan 6, 2014
Clinical News

Winfuran nalfurafine regulatory update

...On Dec. 19, 2013, EMA's CHMP recommended against approval of an MAA from Toray for Winfuran...
...opioid receptor agonist has Orphan Drug designation in the EU to treat hemodialysis-related uremic pruritus. Toray...
...an oral formulation of the product in Japan as Remitch for the indication. In 2011, Toray...
BioCentury | Apr 8, 2013
Financial News

Spectral Diagnostics completes private placement

...C$5.6 million ($5.5 million) Shares: 18.7 million Price: C$0.30 Shares after offering: 119.9 million Investor: Toray...
BioCentury | Mar 25, 2013
Financial News

Spectral Diagnostics amends private placement

...C$5.6 million ($5.5 million) Shares: 18.7 million Price: C$0.30 Shares outstanding prior: 101.3 million Investor: Toray...
BioCentury | Mar 18, 2013
Financial News

Spectral Diagnostics proposes private placement

...C$5 million ($4.9 million) Shares: 16.7 million Price: C$0.30 Shares outstanding prior: 101.3 million Investor: Toray...
BioCentury | Jan 14, 2013
Emerging Company Profile

Trevi: Pain to itch

...according to Good. Toray Industries Inc. markets nalfurafine as Remitch in Japan to treat hemodialysis-related uremic pruritus. Toray...
...& Co. KGaA (Xetra:FRE), Bad Homburg, Germany Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Toray Industries Inc....
Items per page:
1 - 10 of 43